665
Views
6
CrossRef citations to date
0
Altmetric
Review

Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease

, , , &
Pages 51-69 | Received 31 Aug 2017, Accepted 16 Nov 2017, Published online: 22 Nov 2017

References

  • Writing Group M, Mozaffarian D, Benjamin EJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–360.
  • Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–944.
  • Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
  • Trialists CT. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.
  • Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
  • Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol. 2016;67:353–361.
  • Wong ND, Blaha M. IMPROVE-IT: how much really is the IMPROVEment? Am Coll Cardiol. 2014 December 18. Available at: http://www.acc.org/latest-in-cardiology/articles/2014/12/18/11/57/improve-it-how-much-really-is-the-improvement Last accessed 16 October 2017.
  • O’Riordan M. IMPROVE-IT: ‘Modest’ benefit when adding ezetimibe to statins in post-ACS patients. Medscape Medical News from the American Hearth Association 2014 Scientific sessions. November 21, 2014. Available at: https://www.medscape.com/viewarticle/835030 Last accessed 16 October 2017.
  • Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
  • Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College Of Cardiology Task Force On Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92–125.
  • Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;2016(37):2999–3058.
  • Evolocumab (Repatha) – a second PCSK9 inhibitor to lower LDL-cholesterol. Jama. 2015;314:2298–2299.
  • Pollack A New drug sharply lowers cholesterol, but it’s costly. The New York Times. July 24, 2015. Available at: https://www.nytimes.com/2015/07/25/business/us-approves-drug-that-can-sharply-lower-cholesterol-levels.html?mcubz=0 Last accessed 11 June 2017.
  • Amirsadri M, Hassani A. Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men. Daru. 2015;23:56.
  • Ara R, Pandor A, Tumur I, et al. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model. Am J Cardiovasc Drugs. 2008;8:419–427.
  • Ara R, Pandor A, Tumur I, et al. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clin Ther. 2008;30:1508–1523.
  • Arrieta A, Page TF, Veledar E, et al. Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PloS One. 2017;12:e0169761.
  • Barrios V, Lobos JM, Serrano A, et al. Cost-effectiveness analysis of rosuvastatin vs. generic atorvastatin in Spain. J Med Econ. 2012;15:45–54.
  • Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation. 2007;115:2398–2409.
  • Davies GM, Vyas A, Baxter CA. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States. J Med Econ. 2017;20:1–20.
  • Fragoulakis V, Kourlaba G, Maniadakis N. Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece. Clinicoecon Outcomes Res. 2012;4:135–143.
  • Gandhi SK, Jensen MM, Fox KM, et al. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events. Clinicoecon Outcomes Res. 2012;4:1–11.
  • Gandra SR, Villa G, Fonarow GC, et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. 2016;39:313–320.
  • Heart protection study collaborative group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes. 2009;2:65-72.
  • Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. Jama. 2016;316:743–753.
  • Kongnakorn T, Ward A, Roberts CS, et al. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. Value Health. 2009;12:880–887.
  • Korman M, Wisloff T. Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. Eur Heart J Cardiovasc Pharmacother. 2017;pvx010.
  • Lindgren P, Graff J, Olsson AG, et al. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J. 2007;28:1448–1453.
  • MacDonald G. Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham risk score in patients with elevated C-reactive protein. J Am Osteopath Assoc. 2010;110:427–436.
  • Mihaylova B, Schlackow I, Herrington W, et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the study of heart and renal protection (SHARP). Am J Kidney Dis. 2016;67:576–584.
  • Mould-Quevedo JF, Gutiérrez-Ardila MV, Ordóñez Molina JE, et al. Cost-effectiveness analysis of atorvastatin versus rosuvastatin in primary and secondary cardiovascular prevention populations in Brazil and Columbia. Value Health Reg Issues. 2014;5:48–57.
  • Ohsfeldt RL, Gandhi SK, Smolen LJ, et al. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010;13:428–437.
  • Ohsfeldt R, Olsson A, Jensen M, et al. Cost-effectiveness of rosuvastatin 20mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial. J Med Econ. 2012;15:125–133.
  • Onishi Y, Hinotsu S, Nakao YM, et al. Economic evaluation of pravastatin for primary prevention of coronary artery disease based on risk prediction from JALS-ECC in Japan. Value Health Reg Issues. 2013;2:5–12.
  • Peura P, Martikainen J, Soini E, et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin. 2008;24:1823–1832.
  • Reckless J, Davies G, Tunceli K, et al. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study. Value Health. 2010;13:726–734.
  • Slejko JF, Page RL, Sullivan PW. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Curr Med Res Opin. 2010;26:2485–2497.
  • Soini EJO, Davies G, Martikainen JA, et al. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin. 2010;26:25–36.
  • Toth PP, Danese M, Villa G, et al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ. 2017;20:555-564.
  • Tumanan-Mendoza BA, Mendoza VL. Economic evaluation of lipid-lowering therapy in the secondary prevention setting in the Philippines. Value Health Reg Issues. 2013;2:13–20.
  • Van Nooten F, Davies GM, Jukema JW, et al. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Neth Heart J. 2011;19:61–67.
  • Villa G, Lothgren M, Kutikova L, et al. Cost-effectiveness of evolocumab in patients with high cardiovascular risk in Spain. Clin Ther. 2017;39:771–786.
  • Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–1509.
  • Heart protection study collaborative group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
  • Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
  • Talaei M, Sarrafzadegan N, Sadeghi M, et al. Incidence of cardiovascular diseases in an Iranian population: the Isfahan cohort study. Arch Iran Med. 2013;16:138–144.
  • Tanabe N, Iso H, Okada K, et al. Serum total and non-high-density lipoprotein cholesterol and the risk prediction of cardiovascular events - the JALS-ECC. Circ J. 2010;74:1346–1356.
  • Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559.
  • Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504.
  • De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. Jama. 2004;292:1307–1316.
  • LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435.
  • Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Jama. 2005;294:2437–2445.
  • Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152–160.
  • Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the aggrastat to zocor and pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 trials). Am J Cardiol. 2007;100:1047–1051.
  • Schneck DW, Knopp RH, Ballantyne CM, et al. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003;91:33–41.
  • Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama. 2002;288:2709–2716.
  • Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Bmj. 2003;326:1423.
  • Ara R, Tumur I, Pandor A, et al. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Assess. 2008;12:1–212.
  • Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
  • Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–2192.
  • Reckless JP, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract. 2008;62:539–554.
  • D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139:272–281.
  • Roeters Van Lennep HW, Liem AH, Dunselman PH, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin. 2008;24:685–694.
  • National Center for Health Statistics. National health and nutrition examination survey. 192005–2012. Available at: http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm Last accessed 11 June 2017.
  • Ohman EM, Bhatt DL, Steg PG, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151:786–e1.
  • D’Agostino RB Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117:743–753.
  • Wilson PW, D’Agostino R Sr., Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125:695–703.
  • Amgen Inc. Repatha (evolocumab) [package insert]. Available at: http://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/repatha/repatha_pi_hcp_english.ashx Last accessed 11 June 2017.
  • Perez De Isla L, Alonso R, Watts GF, et al. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-Year SAFEHEART registry follow-up. J Am Coll Cardiol. 2016;67:1278–1285.
  • Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:40–51.
  • Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11:1–160.
  • Ara R, Pandor A, Stevens J, et al. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1–118.
  • LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. Jama. 1999;282:2340–2346.
  • Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453–463.
  • Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. Bmj. 2009;338:b2376.
  • Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498–511.
  • Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J. 2001;141:727–734.
  • IMS Institue for Healthcare Informatics. Price declines after branded medicines lose exclusivity in the US. January 2016. Available at: https://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/PhRMA%20Generic%20Price%20Brief%20January%202016.pdf Last accessed 16 October 2017.
  • De Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med. 2010;170:1032–1036.
  • Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER? Arch Intern Med. 2010;170:1073–1077.
  • Green LA. Cholesterol-lowering therapy for primary prevention: still much we don’t know. Arch Intern Med. 2010;170:1007–1008.
  • Ridker PM, Glynn RJ. The JUPITER Trial: responding to the critics. Am J Cardiol. 2010;106:1351–1356.
  • Wei CY, Quek RG, Villa G, et al. A systematic review of cardiovascular outcomes-based cost-effectiveness analyses of lipid-lowering therapies. Pharmaco Econom. 2017;35:297–318.
  • Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185–197.
  • Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.
  • Sanofi Inc. ODYSSEY outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab. Available at: https://clinicaltrials.gov/ct2/show/NCT01663402?term=NCT01663402&rank=1 Last accessed 11 June 2017.
  • Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–1499.
  • Institute for Clinical and Economic Review (ICER). Evolocumab for treatment of high cholesterol: effectiveness and value. September 11, 2017. Available at: https://icer-review.org/wp-content/uploads/2017/06/ICER_PCSK9_NEU_091117.pdf Last accessed 16 October 2017.
  • Auer J, Berent R, Primus C. PCSK9 inhibitors and cardiovascular events. N Engl J Med. 2015;373:773.
  • Goemann IM, Londero TM, Dora JM. PCSK9 inhibitors and cardiovascular events. N Engl J Med. 2015;373:773–774.
  • Sabatine MS, Wasserman SM, Stein EA. PCSK9 inhibitors and cardiovascular events. N Engl J Med. 2015;373:774–775.
  • Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;CD004816.
  • Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs. usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017;177:955–965.
  • Jones M, Tett S, Peeters GM, et al. New-onset diabetes after statin exposure in elderly women: the Australian longitudinal study on women’s health. Drug & Aging. 2017;34:203–209.
  • Ridker PM, Lonn E, Paynter NP, et al. Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. Circulation. 2017;135:1979–1981.
  • Vos E, Biron P, Rose CP. Letter by Vos et al Regarding Article. Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. Circulation. 2017;136:1454–1455.
  • Kleipool EEF, Peters MJL, Muller M. Letter by kleipool et al regarding article. Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. Circulation. 2017;136:1456–1457.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.